DMAC
NASDAQ · Biotechnology
Diamedica Therapeutics Inc
$6.18
+0.13 (+2.15%)
Open$6.04
Previous Close$6.05
Day High$6.26
Day Low$5.81
52W High$10.42
52W Low$3.48
Volume—
Avg Volume166.2K
Market Cap351.85M
P/E Ratio—
EPS$-0.70
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
-32.7% upside
Current
$6.18
$6.18
Target
$4.16
$4.16
$2.49
$4.16 avg
$4.48
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 75.08M | 73.96M | 78.61M |
| Net Income | 7.50M | 6.55M | 6.83M |
| Profit Margin | 10.0% | 8.9% | 8.7% |
| EBITDA | 9.74M | 10.19M | 9.65M |
| Free Cash Flow | 6.22M | 6.24M | 10.05M |
| Rev Growth | +22.4% | +12.6% | +21.2% |
| Debt/Equity | 0.48 | 0.47 | 0.46 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |